PT Kedoya Adyaraya Tbk owns and operates hospitals in Indonesia. The company provides facilities, such as inpatient and outpatient room, operating room, delivery room, HCU, ICU, ICCU, PICU, NICU, emergency room, inpatient, outpatient, covid ICU isolation, endoscopy, operating room, sterilization service center installation, and delivery room. It also offers medical support services, including pharmacy, radiology, CT-Scan, mammography, mobile x-ray, general x-ray, 4D ultrasound, central sterile supply department, fluoroscopy unit, mobile C-Arm, bone densitometry, laparoscopy, bronchoscopy, catheterization laboratory, spirometry, audiometry, electroencephalography, electromyography, electrocardiogram, treadmill, echocardiography, hemodialysis, laser treatment, medical rehabilitation, trauma center, nutrition unit, medical record, panoramic, cephalometry, digital radiography, 4D USG, and 2D/3D USG, as well as laboratories for chemistry, hematology, hemostasis, microbiology, immune-serology, and biomolecular. In addition, the company provides healthcare services in various specialties, such as general surgery, orthopedic surgery, urology, cardiothoracic surgery, plastic surgery, neurosurgery, internist, nephrologist, endocrinologist and metabolic, obstetrics and gynecology specialist, cardiology, neurology, pulmonology, ophthalmologist, hyperbary, pediatrician, acupuncture, speech therapy, oral and maxillofacial, prosthodontics, dentists, psychiatrists, psychologists, nutritionists, skin and venereal specialists, otolaryngologist surgeon, and occupational medicine. The company was founded in 1990 and is headquartered in Jakarta, Indonesia. PT Kedoya Adyaraya Tbk is a subsidiary of PT Sarana Meditama Metropolitan Tbk.
Metrics to compare | RSGK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRSGKPeersSector | |
---|---|---|---|---|
P/E Ratio | 31.4x | 12.8x | −0.6x | |
PEG Ratio | 0.77 | −0.34 | 0.00 | |
Price / Book | 1.5x | 1.2x | 2.6x | |
Price / LTM Sales | 2.7x | 1.3x | 3.2x | |
Upside (Analyst Target) | - | 12.7% | 41.1% | |
Fair Value Upside | Unlock | 0.8% | 5.9% | Unlock |